Cargando…
ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma
Over the last few years, a significant progress has been made in understanding the role of a disintegrin and metalloproteinase 33 (ADAM33) in asthma. The previous observations for the association with asthma have been replicated in over 33 different population samples worldwide. We and others have p...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003756/ https://www.ncbi.nlm.nih.gov/pubmed/24817794 http://dx.doi.org/10.1155/2014/572025 |
_version_ | 1782313879616880640 |
---|---|
author | Tripathi, Priya Awasthi, Shally Gao, Peisong |
author_facet | Tripathi, Priya Awasthi, Shally Gao, Peisong |
author_sort | Tripathi, Priya |
collection | PubMed |
description | Over the last few years, a significant progress has been made in understanding the role of a disintegrin and metalloproteinase 33 (ADAM33) in asthma. The previous observations for the association with asthma have been replicated in over 33 different population samples worldwide. We and others have performed association analysis and meta-analysis and provided further evidence that several polymorphisms in the ADAM33 are risk factors for asthma, especially in the Asian population. Further, several studies have suggested that alterations in epigenetic marks alter the patterns of DNA methylation of ADAM33 and result in potentially adverse biological effects. Finally, while the biological activities of ADAM33 are as yet unknown, ADAM33 may play a possible role in airway remodeling because of its high expression in epithelium, myo/fibroblasts, and airway smooth muscle cells (ASMCs) and its role in promoting angiogenesis and stimulating cell proliferation and differentiation. Thus, ADAM33 represents a promising target for asthma. However, further investigations are clearly needed to discover functional ADAM33 gene polymorphisms and the role of genetic/epigenetic factors in conferring genetic susceptibility to environmental exposure induced asthma as well as biological function in asthma. This, in turn, will unlock the possibility of ADAM33 as a target for asthma therapy. |
format | Online Article Text |
id | pubmed-4003756 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-40037562014-05-11 ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma Tripathi, Priya Awasthi, Shally Gao, Peisong Mediators Inflamm Review Article Over the last few years, a significant progress has been made in understanding the role of a disintegrin and metalloproteinase 33 (ADAM33) in asthma. The previous observations for the association with asthma have been replicated in over 33 different population samples worldwide. We and others have performed association analysis and meta-analysis and provided further evidence that several polymorphisms in the ADAM33 are risk factors for asthma, especially in the Asian population. Further, several studies have suggested that alterations in epigenetic marks alter the patterns of DNA methylation of ADAM33 and result in potentially adverse biological effects. Finally, while the biological activities of ADAM33 are as yet unknown, ADAM33 may play a possible role in airway remodeling because of its high expression in epithelium, myo/fibroblasts, and airway smooth muscle cells (ASMCs) and its role in promoting angiogenesis and stimulating cell proliferation and differentiation. Thus, ADAM33 represents a promising target for asthma. However, further investigations are clearly needed to discover functional ADAM33 gene polymorphisms and the role of genetic/epigenetic factors in conferring genetic susceptibility to environmental exposure induced asthma as well as biological function in asthma. This, in turn, will unlock the possibility of ADAM33 as a target for asthma therapy. Hindawi Publishing Corporation 2014 2014-04-10 /pmc/articles/PMC4003756/ /pubmed/24817794 http://dx.doi.org/10.1155/2014/572025 Text en Copyright © 2014 Priya Tripathi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Tripathi, Priya Awasthi, Shally Gao, Peisong ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma |
title | ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma |
title_full | ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma |
title_fullStr | ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma |
title_full_unstemmed | ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma |
title_short | ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma |
title_sort | adam metallopeptidase domain 33 (adam33): a promising target for asthma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003756/ https://www.ncbi.nlm.nih.gov/pubmed/24817794 http://dx.doi.org/10.1155/2014/572025 |
work_keys_str_mv | AT tripathipriya adammetallopeptidasedomain33adam33apromisingtargetforasthma AT awasthishally adammetallopeptidasedomain33adam33apromisingtargetforasthma AT gaopeisong adammetallopeptidasedomain33adam33apromisingtargetforasthma |